Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck: It’s Not Just Keytruda Driving Future Growth

Feb 05 2020

• By Mandy Jackson

Merck_New_Jersey — Merck posted 11% pharma sales growth in 2019

Related Content

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

Jul 27 2017

Merck & Co's Keytruda Disappoints In Small-Cell Lung Cancer

Jan 07 2020

Eisai And Merck & Co Supercharge Lenvima's Potential

Mar 08 2018

AZ's Lynparza Gets Prostate Cancer Priority Review

Jan 20 2020

Merck Confident In Keytruda’s Dominance In Lung Cancer, Despite Competitors’ Data

Oct 29 2019

Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy

Dec 09 2019

Related Companies

Merck & Co., Inc.

AstraZeneca PLC

Eisai Co., Ltd.

Bayer AG

ArQule, Inc.

Additional Topics

Business Strategies Sales & Earnings Growth Companies Strategy Vaccines ImmunoOncology Commercial BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window